Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-732138 SCHEMBL3682000 | 1.00 | TACR1 (1.00) | TACR1KDM4EMEN1ALDH1A1LMNA | |
| L-732138 SCHEMBL9272011 | 1.00 | TACR1 (1.00) | TACR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL17131465 | 0.94 | TACR1 (0.90) | TACR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL9270710 | 0.89 | TACR1 (0.80) | TACR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL9267643 | 0.89 | TACR1 (1.00) | TACR1KDM4EMEN1ALDH1A1LMNA | |
| L-708568 SCHEMBL8459442 | 0.86 | TACR1 (1.00) | TACR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL30625884 | 0.86 | TACR1 (0.80) | TACR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL9266278 | 0.86 | TACR1 (0.80) | TACR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL9270608 | 0.85 | TACR1 (0.75) | TACR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL9001383 | 0.85 | TACR1 (1.00) | TACR1KDM4EMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | claimed |
| EP-2966448-B1 | METHOD FOR THE PREDICTION OR PROGNOSIS OF THE RESPONSE OF A HUMAN SUBJECT SUFFERING FROM CANCER TO TREATMENT WITH AN ANTAGONIST OF THE NK1 RECEPTOR | SERVICIO ANDALUZ DE SALUD (ES) | 2025-03-05 | — | — | EP | claimed |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2024-08-01 | — | — | US | claimed |
| EP-3870236-B1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-09 | — | — | EP | claimed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | claimed |
| CN-114206849-A | Therapeutic methods for treating non-infectious ocular immunoinflammatory disorders | 斯格本斯眼科研究所有限公司 | 2022-03-18 | — | — | CN | claimed |
| US-20220031849-A1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-03 | — | — | US | claimed |
| EP-4255400-B1 | NEUROKININ INHIBITORS SUCH AS APREPITANT FOR TREATING NON SMALL CELL LUNG CARCINOMA WITHOUT MUTATIONS | PLUS VITECH S L (ES) | 2025-12-24 | — | — | EP | disclosed |
| US-20250302892-A1 | PROBIOTIC FOR USE IN THE TREATMENT OF INFLAMMATORY ALTERATIONS OF THE INTESTINAL MUCOSA, PARTICULARLY OBESITY | CERBIOS-PHARMA SA (CH) | 2025-10-02 | — | — | US | disclosed |
| US-12419861-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-i | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2025-09-23 | — | — | US | disclosed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | disclosed |
| EP-4543422-A1 | PROBIOTIC FOR USE IN THE TREATMENT OF INFLAMMATORY ALTERATIONS OF THE INTESTINAL MUCOSA, PARTICULARLY OBESITY | CERBIOS-PHARMA SA (CH) | 2025-04-30 | — | — | EP | disclosed |
| EP-2966448-B1 | METHOD FOR THE PREDICTION OR PROGNOSIS OF THE RESPONSE OF A HUMAN SUBJECT SUFFERING FROM CANCER TO TREATMENT WITH AN ANTAGONIST OF THE NK1 RECEPTOR | SERVICIO ANDALUZ DE SALUD (ES) | 2025-03-05 | — | — | EP | disclosed |
| WO-2022074588-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022074587-A1 | MU-OPIOID RECEPTOR AGONISTS AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106279-A1 | CLASS OF MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3976594-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | The Schepens Eye Research Institute, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114206849-A | Therapeutic methods for treating non-infectious ocular immunoinflammatory disorders | 斯格本斯眼科研究所有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022038131-A1 | METHOD FOR THE PREDICTION OF PROGRESSION OR PROGNOSIS OF THE RESPONSE OF A SUBJECT SUFFERING FROM ACUTE ORGAN DAMAGE | Plus Vitech, S.L. (ES) | 2022-02-24 | — | — | WO | disclosed |
| US-20220031849-A1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885KDM4E 3729/4885MEN1 1273/4885 |
| US-20220106279-A1 | CLASS OF MU-OPIOID RECEPTOR AGONISTS | OPRM1, OPRL1, OPRK1 | TACR1 12/4885KDM4E 2011/4885MEN1 4601/4885 |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | TACR1 226/4885KDM4E 3729/4885MEN1 1273/4885 |
| US-20220031849-A1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | GPR88, GPR65, ARRB1 | TACR1 250/4885KDM4E 4361/4885MEN1 3215/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885KDM4E 3729/4885MEN1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.